Candel Therapeutics Inc.
February 25, 2025 - by Joey Ramson
$CADL is the biggest laggard in the Prism MarketView Pharmaceuticals index despite announcing positive final survival data from its Phase 2 trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
